News | October 27, 2021
Cipla consolidated net profit at Rs 711.36 cr. in Q2FY22
Cipla has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Subscribe To Our Newsletter & Stay Updated
